| Document |
Document Title |
|
JP4091860B2 |
|
|
JP2008115195A |
To provide a novel inhibitor for protein kinase aurora-2 and GSK-3.The novel pyrazole compound is represented by formula (II) (wherein the ring C is selected from phenyl, pyridinyl, pyrimidinyl, pyridazynyl, pyrazinyl, or 1,2,4-triazinyl...
|
|
JP4084570B2 |
Compounds of formula I: wherein A, D, Ar1, E and Ar2 are as defined in the specification, processes for preparing them, pharmaceutical compositions containing them and their use in therapy, especially in the treatment or prophylaxis of p...
|
|
JP2008510771A |
Disclosed are new dihydropteridinones of general formula (I) wherein the groups R1 to R5, Ra to Rc, W, Q1 and Q2 have the meanings given in the claims and specification, the isomers thereof and the use thereof for preparing a pharmaceuti...
|
|
JP2008510750A |
Dihydropteridinone derivatives (I) are new. Dihydropteridinone derivatives of formula (I) and their tautomers, isomers, acid addition salts, solvates and hydrates are new. L = a bond, A, OA or N(R 7>)A; A = 1-6C alkylene, 2-6C alkenylene...
|
|
JP2008510770A |
Disclosed compounds of general formula (1) wherein L, Q1, Q2, X, Y, Ra, Rb, Rc, R1, R2, R3 and R4 are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and ...
|
|
JP4074509B2 |
The present invention relates to methods and intermediates for preparing compounds of the formula 1 and the pharmaceutically acceptable salts and solvates thereof, as well as structurally related compounds, wherein R<1>, R<2> and R<15> a...
|
|
JP2008509953A |
Disclosed are hydrates and polymorphs of 4- [[(7R)-8-cyclopentyl-7 -ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]
-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide: as well as, processes for preparing them and their use as ph...
|
|
JP2008509949A |
The present invention relates to the use of a compound of general Formula (1),optionally in form of its tautomers, racemates, enantiomers, diastereomers and the mixtures thereof and optionally in form of the pharmacologically acceptable ...
|
|
JP2008056585A |
To provide a compound which has a long life by excitation and can form a charge separation state of high energy and a product using the same.An electron donor/receptor connection type flavin molecule is obtained by introducing an electro...
|
|
JP2008504281A |
The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activit...
|
|
JP2008502630A |
Polyunsaturated fatty acid ("PUFA") or a pharmacologically acceptable salt or derivative thereof (such as EPA and/or DHA) is used in combination with at least one of an immunosuppressive agent or an antineoplastic agent, said agent(s) ha...
|
|
JP4038624B2 |
To obtain a new compound having excellent effects on insect pests such as various agricultural and forestry, horticultural, stored grain insect pests, sanitary insect pests or nematodes damaging rice plants, vegetables, fruit trees, etc....
|
|
JP2008007515A |
To provide a novel NPY receptor, particularly a non-peptidic antagonist of an NPY1 receptor.A compound being substituted with a specific alkylenediamine and having a specific modified mono-, bi-, or tricyclic heterocyclic core is used. T...
|
|
JP4031705B2 |
The present invention relates generally to a process for recovering copper and other metal values from metal-containing materials using controlled, super-fine grinding and medium temperature pressure leaching. Processes embodying aspects...
|
|
JP2007536210A |
Crystal forms of (6R)-L-erythro-tetrahydrobiopterin dihydrochloride, hydrates and solvates and processes for their preparation are provided. These crystal forms are either intermediates for the preparation of stable polymorphic form B or...
|
|
JP2007314890A |
To provide an effective method for efficiently recovering copper from a copper-containing substance (particularly copper from a copper sulfide such as chalcopyrite and chalcocite), which realizes a high copper recovery rate at a reduced ...
|
|
JP2007533610A |
Compounds of general formula (V) where R2 is an N-containing heterocyclic (H/c) radical, other than morpholinyl or piperazinyl, attached to the ring via an N atom; benzyl- or phenylethyl-amino; H/c-substituted alkylamino, alkyloxy or alk...
|
|
JP2007533617A |
This invention relates to the use of a group of pteridine derivatives, their pharmaceutically acceptable salts, N-oxides, solvates, dihydro- and tetrahydroderivatives and enantiomers, for the manufacture of a medicament for the preventio...
|
|
JP2007291135A |
To provide the improvement of pharmaceutical or nutritive compositions for human. The invention relates to products for complete nutrition of infants or diseased or elderly persons. The products are characterized by increased levels of f...
|
|
JP2007530417A |
Provided herein are methods and compositions for modulating the activity of sirtuin deacetylase protein family members; p53 activity; apoptosis; lifespan and sensitivity to stress of cells and organisms. Exemplary methods comprise contac...
|
|
JP3996103B2 |
|
|
JP2007254479A |
To provide an immunosuppressant with a reduced side reaction, having simple medication plan and/or is orally active. The invention relates to the immunoregulatory phosphorus substituted compound, composition containing such compound, and...
|
|
JP2007238621A |
To provide a therapeutic antiviral preparation having improved pharmacological characteristics, a dosing regimen for a new antiviral compound not more troublesome than the conventional regimen, or an assay method determining the presence...
|
|
JP2007523095A |
The inventive method for the production of crystalline (6RS)-N(5)-formyl-5,6,7,8-tetrahydrofolic acid or amorphic (6S)-N(5)-formyl-5,6,7,8-tetrahydrofolic acid is characterized in that an aqueous solution of (6RS)- or (6S)-calcium folina...
|
|
JP2007504273T5 |
|
|
JP2007513940A |
The invention relates to the use of enzymatic inhibitors of h-PRUNE and to screening method for the prevention and treatment of the metastases of tumours overexpressing h-PRUNE thereof and to the diagnostic kit for the prognosis of said ...
|
|
JP2007512369A |
The invention encompasses a novel method of treating inflammatory disease, such as rheumatoid arthritis, and novel methods of identifying and screening for drugs useful in the treatment of inflammatory diseases and their clinical symptom...
|
|
JP2007510745A |
This invention provides fused heterocyclic compounds, pharmaceutical compositions of the compounds, and methods of using the compounds for the treatment of, inter alia, IL-12 related disease and disorders.
|
|
JP2007510660A |
Compounds, compositions and methods useful for treating cellular proliferative diseases and disorders by modulating the activity of KSP are disclosed.
|
|
JP2007509985A |
Capsaicin receptor agonists are provided. Such compounds are ligands that may be used to modulate VR1 activity in vivo or in vitro, and are particularly useful in the treatment of conditions responsive to capsaicin receptor activation in...
|
|
JP2007508355A |
This invention relates to a group of substituted pteridine derivatives, their pharmaceutically acceptable salts, N-oxides, solvates, dihydro- and tetrahydro-derivatives and enantiomers, possessing unexpectedly desirable pharmaceutical pr...
|
|
JP2007507494A |
There are disclosed novel compounds of formula (I) wherein A, R1, R2, R3 and X are as defined in the specification, and pharmaceutically acceptable salts thereof, together with processes for their preparation, pharmaceutical compositions...
|
|
JP2007504273A |
Compositions and methods involving administration of agents useful for the treatment, prevention, inhibition, etc., of fibrous adhesions.
|
|
JP2007501861A |
A variety of small molecule, guanidine-containing molecules capable of acting as MC4-R agonists are provided. The compounds are useful in treating MC4-R mediated diseases when administered to subjects. The compounds have the structures V...
|
|
JP3876254B2 |
The invention relates to novel dihydropteridinones of general formula (I), wherein the groups X, R<1>, R<2>, R<3>, R<4>, R<5> and R<7> are defined as per the claims and the description, to the isomers thereof, to a method for producing s...
|
|
JP3876265B2 |
The invention relates to novel dihydropteridinones of general formula (I), wherein rests L, R<1>-R<5 >have the significance indicated in claims and a specification, in the isomers thereof, in a method for producing and using said dihydro...
|
|
JP2007501227A |
The present invention relates to pharmaceutically active ornithine compounds, particularly to pharmaceutically acceptable ammonium salts of N-acyl derivatives of N(4-amino-4-deoxypteroyl)-L-ornithine compounds; and methods of treatment a...
|
|
JP3872759B2 |
To provide a method for producing riboflavin in a high yield and a high production rate by improving dispersibility of a vegetable oil or an animal oil to a culture medium in the method for culturing a riboflavin producing microorganism ...
|
|
JP2006528224A |
Novel poly-substituted pteridinediones (lumazines), and mono- or polysubstituted 2-thiolumazines, 4-thiolumazines or 2,4-dithiolumazines, having disclosed substituents in positions 1, 3, 6 and 7 of the pteridine ring, and pharmaceuticall...
|
|
JP3845307B2 |
Therapeutic or preventive agents for myocardial infarction containing as the active ingredient compounds of general formula (I) or salts thereof wherein R1 is CH2, CH2CH2,CH2O, CH2S or CH2SO; R2 is hydrogen, C1-C4 alkyl or benzyl; R3 is ...
|
|
JP2006523689A |
In one embodiment, the present invention relates to a new class of ammonium salts of Ndelta-acyl derivatives of Nalpha-(4-amino-4-deoxypteroyl)-L-ornithine compounds having a structure according to formula II-IV. Formula II has the struc...
|
|
JP2006523237A |
The invention provides novel prodrugs of inhibitors of PI-3 kinase. The novel compounds are LY294002 and analogs thereof comprising a reversibly quaternized amine.
|
|
JP2006522763A |
The present invention relates to an improved process for preparing riboflavin of the B/C modification in granule form. Furthermore, the invention relates to the riboflavin preparation process wherein riboflavin of the A modification is (...
|
|
JP3825969B2 |
To provide an electric conduction element using a liquid crystal compound, with which high electrical conductivity is attained as a career transportation layer by improving high career mobility and career injection characteristic from an...
|
|
JP2006248964A |
To obtain a new pterin derivative exhibiting high solubility in water.The pterin compound is represented by formula (I) (R1 is a 1-20C saturated or unsaturated aliphatic hydrocarbon group which may be substituted, a 3-20C saturated or un...
|
|
JP2006230299A |
To provide a method for deciding effectiveness of methotrexate therapy for an arthrorheumatism patient, and to provide a kit therefor.The method for deciding effect and dose of methotrexate for the arthrorheumatism patient is characteriz...
|
|
JP2006516561A |
The present invention provides substituted 2-aminopyridines of formula I, wherein R<1>, A<1>, W, X, and Y are as defined in the specification, useful in treating cell proliferative disorders. The novel compounds of the present invention ...
|
|
JP2006508984A |
A method and compositions for treating persistent pulmonary hypertension in human newborns that deploys an intravenous infusion of a modified drug formed by adding one or more of a predetermined chemical arrangement to an efficacious par...
|
|
JP2006508985A |
A method for modifying at least one non-ester-containing parent compound, and the compounds produced using such method, which compounds are deployed to temporarily incapacitate at least one subject are disclosed. The modified compounds a...
|
